Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery

In the US, obesity rates are increasing greatly. The Centers for Disease Control and Prevention estimates that 68.5% of Americans, including 63.9% of adult women older than 20 years, are overweight (body mass index between 25 kg/m2 and 29.9 kg/m2) or obese (body mass index >30 kg/m2). In light of this, it is not surprising that the rates of bariatric surgery have also been increasing. When cons...

Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.

OBJECTIVE To determine whether use of the injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) affects the risk of breast cancer in women. DESIGN A population based case-control study. SETTING Nationwide community study. SUBJECTS 891 Women aged 25-54 with newly diagnosed breast cancer were compared with 1864 women selected at random from the electoral rolls. INTERVE...

Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss.

Medroxyprogesterone acetate [Depo Provera] injections. Development of striae.

A young girl developed extensive striae while on Depo Provera injections. She had gained some weight during the treatment. Endocrinal investigations were negative. The development of striae was attributed to her weight gain.

Subcutaneous depo-medroxyprogesterone acetate.

To cite: Cameron S. Journal of Family Planning and Reproductive Health Care 2013;39:75–77. INTRODUCTION Since 2004, a micronised formulation of depo-medroxyprogesterone acetate (DMPA) that is delivered as a subcutaneous injection has been available. It is currently in clinical use in the USA and in nine countries throughout Europe. As of March 2013 this product is being marketed in the UK as Sa...